1. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL:
Calcifi cation of human vascular cells in vitro is correlated with
high levels of matrix Gla protein and low levels of osteopontin
expression. Arterioscler Thromb Vasc Biol 1998; 18:379-388
2. Ross R: Atherosclerosis --an infl ammatory disease. N Engl J Med
1999;340:115-126
3. Meema HE, Oreopoulos DG, deVeber GA: Arterial calcifi cations
in severe chronic renal disease and their relationship to dialysis
treatment, renal transplant and parathyroidectomy. Radiology 1976;
121:315-321
4. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association
between chronic kidney disease and coronary artery calcifi cation:
The Dallas Heart Study. J Am Soc Nephrol 2005; 16-507-513
5. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R:
Coronary risk factors and plaque morphology in men with coronary
disease who died suddenly. N Engl J Med 1997; 336, 1276-1282
6. Doherty TM, Asotra K, Fitzpatrick, LA, Qiao JH, Wilkin DJ,
Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB: Calcifi cation
in atherosclerosis: Bone biology and chronic infl ammation at the
arterial crossroads. Proc Natl Acad Sci 2003; 100: 11201-11206
7. Collett GD, Canfi eld AE: Angiogenesis and pericytes in the initiation
of ectopic calcifi cation. Circ Res 2005; 96: 930-938
8. Dellegrottaglie S, Sanz J, Rajagopalan. S: Molecular determinants of
vascular calcifi cation: A bench to bedside view. Current Molecular
Medicine 2006; 6: 515-524
9. Hruska KA, Suresh M, Saab G: Bone morphogenetic proteins in
vascular calcifi cation. Circ Res 2005; 97:105-114
10. Kazama JJ: Osteoprotegerin and bone mineral metabolism in renal
failure. Current Opinion in Nephrology and Hypertension. 2004;
13:411-415
11. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP,
Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ:
Differential expression of bone matrix regulatory proteins in human
atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21:
1998-2003
12. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S,
Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet
WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal
osteoclasts and prevents vascular calcifi cation by blocking a process
resembling osteoclastogenesis. J Exp Med 2000; 192:463-474
13. Gyda M, Corisdeo S, Zaidi M, Troen BR: Macrophage colonystimulating
factor suppresses osteoblast formation. Biochem
Biophys Res Commun 2001; 285:328-334
14. Ahlen J, Andersson S, Mukohyama H, Roth C, Backman A,
Conaway HH, Lerner UH: Characterization of the bone-resorptive
effect of interleukin-11 in cultured mouse calvarial bones. Bone
2002; 31:242-251
15. Aubin JE, Bonnelye E: Osteoprotegerin and its ligand: A new
paradigm for regulation of osteoclastogenesis and bone resorption.
Osteoporos Int 2000; 11:905-913
16. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J,
Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein
alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically
acting inhibitor of ectopic calcifi cation. J Clin Invest 2003; 112:
357-366
17. Moe SM, Reslerova M, Ketteler M, O’neill K, Duan D, Koczman J,
Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcifi cation
inhibitors in the pathogenesis of vascular calcifi cation in chronic
kidney disease (CKD). Kidney Int 2005; 67(6):2295-2304
18. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan, CM: Matrix
gla protein is regulated by a mechanism functionally related to the
calcium-sensing receptor. Biochem Biophys Res Commun 2000;
277:736-740
19. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR,
Karsenty G: Spontaneous calcifi cation of arteries and cartilage in
mice lacking matrix GLA protein. Nature 1997; 386:78-81
20. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O’Donnell CJ,
Wilson PW: Bone loss and the progression of abdominal aortic
calcifi cation over a 25 year period: The Framingham Heart Study.
Calcif Tissue Int 2001; 68:271-276
21. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM,
Weissberg PL: Apoptosis regulates human vascular calcifi cation in
Cilt/Vol: 19, No: 2, 2010, Sayfa/Page: 82-87
87
Türkmen K, Tonbul HZ: Kronik Böbrek Hastalığında Vasküler Kalsifi kasyon
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
vitro: Evidence for initiation of vascular calcifi cation by apoptotic
bodies. Circ Res 2000; 24 87:1055-1062
22. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the
progression of coronary and aortic calcifi cation in hemodialysis
patients. Kidney Int 2002; 62:245-252
23. Raggi P. Effects of excess calcium load on the cardiovascular
system measured with electron beam tomography in end-stage renal
disease. Nephrol. Dial. Transplant 2002; 17: 332-335.
24. Nemeth EF, Bennett SA: Tricking the parathyroid gland with novel
calcimimetic agents Nephrol Dial Transplant 1998; 13:1923-1925.
25. K/DOQI clinical practice guidelines for cardiovascular disease in
dialysis patients. Am J Kidney Dis 2005; 45(4 suppl 3):S1-S153
26. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular
calcifi cation in long term haemodialysis patients in a single unit: A
retrospective analysis. Nephron 1997; 77:37-43
27. Moe SM, Chertow GM, Cobum JW, Quarles LD, Goodman WG,
Block GA, et al: Achiving NKF-K/DOQI bone metabolism and
disease treatment goals with cinacalcet HCL. Kidney Int 2005; 67:
760-771
28. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential
effects of Vitamin D receptor activators on vascular calcifi cation in
uremic rats. Kidney Int 2007; 72:709-715
29. Tsuruta Y, Ohbayashi T, Fujii M, Myochin H, Mizutani R, Narita
M, Maeda K: Change in coronary artery calcifi cation score due to
cinacalcet hydrochloride administration. Ther Apher Dial 2008; 1:
34-37
30. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N,
Wakita S, Wada M: Cinacalcet suppresses calcifi cation of the aorta
and heart in uremic rats. 1: Kidney Int 2008; 74:1270-1277
31. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ:
Prognostic value of cardiac risk factors and coronary artery calcium
screening for all-cause mortality. Radiology 2003; 228:826-833
32. Raggi P, Shaw LJ, Berman DS, Callister TQ: Prognostic value of
coronary artery calcium screening in subjects with and without
diabetes. J. Am Coll Cardiol 2004; 43:1663-1669
33. Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P,
Stanford W, Wolfkiel C, Georgiou D, Budoff M, Reed J: Prognostic
value of coronary calcifi cation and angiographic stenoses in patients
undergoing coronary angiography. J Am Coll Cardiol 1996; 27:
285-290
34. Raggi P, Callister TQ, Cooil B, He ZX, Lippolis NJ, Russo DJ,
Zelinger A, Mahmarian JJ: Identifi cation of patients at increased
risk of fi rst unheralded acute myocardial infarction by electronbeam
computed tomography. Circulation 2000; 101:850-855
35. Derici U, El Nahas AM: Vascular calcifi cations in uremia: Old
concepts and new insights. Semin Dial 2006; 19(1):60-68
Thank you for copying data from http://www.arastirmax.com